The Cardiovascular Therapy and Prevention has been published since 2002. It is one of the official journals of the Society of Cardiology of the Russian Federation. The target audience of this peer-reviewed journal is cardiologists and internal disease specialists. The journal is primarily focused on questions of prevention, epidemiology and cardiac pharmacotherapy. It also publishes lectures and literature reviews on various problems of modern cardiology, reports on new diagnostic methods, and other information which is important for the practitioners.

The Cardiovascular Therapy and Prevention aims to ensure that its publications fulfill the requirements of international publishing standards, such as the Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication, by the International Committee of Medical Journal Editors, ICMJE (, and the recommendations by the Committee on Publication Ethics, COPE (

All clinical trials should be performed and described in full accordance with the CONSORT standards (

Manuscripts should be forwarded as electronic documents on e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., and printable version should be sent by post on address: 101990, Moscow, Petroverigsky pereulok, 10. Cardiovascular Therapy and Prevention.

Telephone +7 (495) 621—93—02

  1. Manuscripts should be accompanied by a cover letter, which should include the following information: 1) the manuscript is not being considered for publication by any other journal; 2) it has not been published previously; 3) potential conflict of interests has been fully disclosed; 4) all authors have read and approved the manuscript; 5) and the authors are responsible for the validity and integrity of the work as a whole. The cover letter should also contain the contact details of the corresponding author.

If the manuscript is a part of a dissertation/thesis, the proposed defense time should be specified.

The cover letter is presented on a separate page.

The authorship information is provided on a separate page and should contain the following: authors' names, institutional affiliations, and positions. For at least one author, the contact details are specified, including e-mail address, telephone number, and mailing address. This address will be used after the publication of the manuscript, for sending 1 (one) respective issue of the journal to the authors.

If the list of authors includes more than 4 people, the individual contribution should be specified for each author. When the manuscript is authored by a group of authors, all the group members should fully qualify for the authorship. Authorship credit could be based on: 1) contributions to conception and design of the study, or analysis and interpretation of the data; 2) drafting the article or revising it critically for important intellectual content; 3) final approval of the version to be published.

  1. The Cardiovascular Therapy and Prevention accepts the following manuscripts:

1) Original papers present the results of clinical studies. The word limit is 3,000 (including references, tables, and figure legends). The maximal number of references is 15. The structured abstract should contain 5 sections (Aim, Material and Methods, Results, Conclusion, and Key words), and be no longer than 300 words.

2) Lectures, or clinically oriented reviews, are written by experts in broader areas of medicine. Lectures could be focused on epidemiology, pathophysiology, diagnostics, treatment, and prevention. The word limit is 5,000 (including references, tables, and figure legends). The maximal reference number is 80. The unstructured abstract is no longer than 150 words.

3) Literature reviews are focused on more specific topics, compared to lectures. The word limit is 4,500 (including references, tables, and figure legends). The maximal reference number is 50. The unstructured abstract is up to 150 words.

4) Clinical case is a brief report on a complex diagnostic problem and its solution, or a description of a rare clinical observation. The word limit is 600 (including references, tables, and figure legends). The maximal number of references is 5. No abstract is required.

5) Clinical opinion informs the readers on the topics of cardiovascular medicine and related disciplines. The word limit is 2,500 (including references, tables, and figure legends). The maximal number of references is 15.

  1. Original articles should be structured into the following sections: Introduction, Material and Methods, Results, Discussion, and Conclusion. Reviews and lectures can be formatted differently.   

All manuscript pages should be single-sided and printed on A4 paper, using font size 12, 1.5 interval, all margins of 2.0 cm, and left alignment. The data should be reported using SI units. Between a percentage symbol and a preceding digit, there should be a space character; p value is reported with decimal points (p<0,0001). The text should be carefully edited and proofread by the author (s). Footnotes for the quotations should specify the original source (author (s), year). Authors are responsible for the accuracy of quotations, reported medication doses, and other presented information.

All the pages should be numbered consecutively, beginning with title page.

  1. Article title should be capitalized and presented without word hyphenation, in semi-bold font (Times New Roman BOLD, 12 pt). Family names and initials of authors are italicized: Ivanov I.I., Petrov P.P.

The full name of the institution (s) where the study was conducted should be followed by the name of the city and country. The footnotes are presented as Arabic numerals, after the author's family name and after the name of the respective institution.

The first page of the manuscript (with the title and the beginning of the text) should be signed by all authors.

The abstract form is defined by the manuscript type: a structured abstract has 5 sections (Aim, Material and Methods, Results, Conclusion, and Key words), while an unstructured abstract contains a brief work description and Key words.

The maximal number of Key words is 6.

Illustrations (diagrams, charts, or figures) are accepted in electronic formats MS Excel, Adobe Illustrator, Corel Draw, or MS PowerPoint. Photographs should have a minimal resolution of 300 pixels per inch. The name of each illustration file should include the family name of the first author (in Latin characters) and the illustration number, according to its order of citation in the text.

Titles and legends for illustrations are printed on a separate page. The duplication of information in tables and illustrations should be avoided.

All published manuscripts are reviewed by a statistical expert and should comply with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (AnnInternMed1997 126: 36—47). It is also recommended to follow specialised guidelines, such as the ones by the European Heart Journal:

Statistical methods should be described in detail in the Material and Methods section.

  1. Abbreviations should be standard and clear to the readers. Authors must avoid using abbreviations which could have more than one meaning.

The list of abbreviations and their definitions should follow the standards for research publications. Abbreviations are used for medical terms frequently used in the manuscript (for example, AH, CHF, or FC) and for clinical trial names (such as SOLVD, TIMI, or HOPE).

  1. Tables should capture information concisely and display it efficiently. Each table is printed on a separate page, together with its number, title, and explanatory information (footnotes and abbreviations).

All tables should identify the measurement units and specify the data presentation (for example, M±m; M±SD; median; mode; percentiles, etc.). All numbers, totals, and percentages should be double-checked and correspond to the respective part of the text. If necessary, authors should place explanatory matter in footnotes. The following symbols should be used for footnotes, in sequence: *,†,§,||,¶, #, **, ††, etc. Abbreviations should be listed alphabetically in the table footnote.

Every first mention of each illustration and table in the text should be highlighted in yellow. If the reference to the illustration or table is a part of a sentence, it is spelled-out as "Figure 1" or "Table 1"; the reference in brackets is abbreviated as (Fig. 1) or (Tab. 1).

  1. References are printed on a separate page, using 1.5 interval. All references in the text should also be in the list of references, and vice versa. Citing unpublished or old (over 10 years) work is not permitted; an occasional exception could be made for selected highly informative sources.

The reference should contain up to three family names of the authors; the following names are abbreviated as "и др." for Russian sources, or "et al." for international sources. For journal articles, the reference contains family names and initials of the authors; article title; journal title; publication year; volume and issue; and page numbers. For articles from proceedings, it contains family name and initials; article title; proceedings title; publication place; publication year; and page numbers.

References should be numbered consecutively in the order in which they appear in the text. References are identified in the text by Arabic numerals in square brackets, for example [1]. In the list of references, each reference starts from a new line.

In order to increase the citation index of the journal, all Russian sources should be transliterated, i.e. authors' names and journal titles are transliterated using the standard coding, while article titles are translated. Transliteration could be performed using various online resources, such as

All Russian sources should be transliterated.

Authors are responsible for the accuracy of the references.

The references should comply with the format recommended by the American National Information Standards Organization (NISO), adapted by the National Library of Medicine (NLM; for its databases (Library's MEDLINE/PubMed database). The titles of journals should be abbreviated according to the format accepted by a specific journal; this information could be found on the journal website, or in the Index Medicus.

Citation examples:


Smith A., Jones B., Clements S. Clinical transplantation of tissue-engineered airway. Lancet 2008; 372:1201—09.

Transliterated Russian article:

Shalnova S. A., Deev A. D. Russian mortality trends in the early XXI century: official statistics data. Cardiovascular Therapy and Prevention 2011; 10 (6):5—10. Russian (Шальнова С. А., Деев А. Д. Тенденции смертности в России в начале XXI века по данным официальной статистики. Кардиоваскулярная терапия и профилактика 2011; 10 (6):5—10).


Shlyakhto E.V., Konradi A.O., Tsyrlin V.A. The autonomic nervous system and hypertension. SPb.: Meditsinskoe izdatel'stvo; 2008. Russian (Шляхто Е.В., Конради А.О., Цырлин В.А. Вегетативная нервная система и артериальная гипертензия. СПб.: Медицинское издательство; 2008).


Nichols WW, O'Rourke MF. Aging, high blood pressure and disease in humans. In: Arnold E, ed. McDonald's Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles. 3rd ed. London/Melbourne/Auckland: Lea and Febiger; 1990. p.398—420.

Russian chapter:

Diagnostics and treatment of chronic heart failure. In. National clinical guidelines 4th ed. Moscow: Silicea-Polygraf; 2011. pp.203—293. Russian (Диагностика и лечение хронической сердечной недостаточности. В кн: Национальные клинические рекомендации. 4-е издание. М.: Силицея-Полиграф; 2011.сс.203—296).


Panteghini M. Recommendations on use of biochemical markers in acute coronary syndrome: IFCC proposals. eJIFCC 14. (28 May 2004)

  1. The journal accepts the articles describing Phase 3 and 4 clinical studies. Inclusion of women and ethnic minorities in clinical studies and analytical reviews is encouraged. The studies should be performed in accordance with Law 61 "On Circulation of Pharmaceuticals" from April 12th 2010 (if they were fully or partly performed in the Russian Federation), and/or with Good Clinical Practice principles. The participants should be informed about the aims and major features of the study before providing written informed consent. Authors should clarify the procedure of obtaining informed consent while describing the study protocol in the Material and Methods section. The approval of the study protocol by the Ethics Committee should also be mentioned. If study methods include X-ray exposure, detailed description and exposure doses should be presented in Material and Methods.

Patients have a right to privacy, therefore, identifying information, including images, names, initials, or hospital record numbers, should not be published. If is information is essential for scientific purposes, the patient (or parent or guardian) should give written informed consent for its publication in print or electronic media. If necessary, the journal may request this written informed consent from the authors.


The study was performed according to the Good Clinical Practice guidelines and the Declaration of Helsinki. The study protocol was approved by the Ethics Committees of all the study centres involved. Written informed consent was obtained from all participants prior to their inclusion in the study.

  1. Conflict-of-interest notification page.

This separate page contains the authors' disclosure of any potential financial and personal relationships which can lead to conflicts of interests related to the submitted manuscript. The funding sources should be specified. In the case of no potential conflicts of interest, it is stated "Conflict of interest not declared".

Conflict of interest exists when an author (or the author's institution), reviewer, or editor has financial or personal relationships that inappropriately influence their actions and decisions. Not all relationships represent true conflict of interest.

The potential for conflict of interest can exist regardless of whether an individual believes that the relationship affects his or her scientific judgment. Financial relationships (such as employment, consultancies, stock ownership, honoraria, and paid expert testimony) are the most easily identifiable conflicts of interests and the most likely to undermine the credibility of the journal, the authors, and of science itself. However, conflicts can occur for other reasons, such as personal relationships, academic competition, and intellectual passion.

Authors should describe the role of the study sponsor, if any, in study design; collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication. If the sponsors had no such involvement, the authors should so state.

  1. All contributors who do not meet the criteria for authorship should be listed in Acknowledgements. Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance, or a departmental chairperson who provided only general support. Financial and material support should also be acknowledged. Groups of persons who have contributed to the paper, but whose contributions do not justify authorship, may be listed under such headings as "clinical investigators" or "participating investigators". Their function or contribution should be described — for example, "served as scientific advisors", "critically reviewed the study proposal", "collected data", or "provided and cared for study participants". Because readers may infer their endorsement of the data and conclusions, these persons must give written permission to be acknowledged. The word limit for Acknowledgements is 100 words.
  2. Manuscript publication is free for the Author. After the paper is published, the Editor sends 1 (one) journal issue to the respective Author. The Author's copy of the paper can be sent out only within the Russian Federation. Authors from Baltic or CIS countries can be e-mailed a PDF copy of the respective journal issue; the requests should be addressed to: This email address is being protected from spambots. You need JavaScript enabled to view it..


This section regulates the relationship between the editorial office of the Cardiovascular Therapy and Prevention (referred to as "Editor"), the publishing house Silicea-Poligraf ("Publisher"), and the author (s) submitting their manuscript to the Cardiovascular Therapy and Prevention ("Author").

By submitting the manuscript to the Editor, the Author agrees that the Editor and the Publisher acquire an exclusive licence to use the manuscript (all submitted copyright material, such as photographs, illustrations, diagrams, tables, etc.), i.e. to reproduce this material in print or online; to distribute it; to translate into any other languages; to export and import journal issues containing the Author's paper for distribution purposes; and to disseminate the contents of the paper.

The Editor reserves the right to abridge and edit the manuscript content; to perform scientific editing; to abridge and edit the papers; and to alter the design of illustrations, diagrams, or tables in accordance with the journal standards, without distorting the meaning of the presented information.

The Editor and the Publisher can accompany the paper with any illustrations or advertisement materials, and/or grant this right to a third party.

The Editor and the Publisher can transfer the exclusive licence to use the manuscript, which they were granted by the Author, to a third party. They can also prohibit the third party from any commercial use of the materials published in the journal.

The author should guarantee the possession of an exclusive right to use the submitted materials. If this guarantee is breached, and a respective complaint is received by the Editor or the Publisher, the Author is responsible for the settlement of the conflict and coverage of potential costs. The Editor and the Publisher are not responsible to a third party for the guarantee breach by the Author.

The Author retains the right to use the published material, its parts and fragments, for personal purposes (including research and teaching).

The Author grants the above-mentioned exclusive licence to the Editor and the Publisher without any time or location-related constraints, covering all countries and the Russian Federation in particular.

The exclusive licence is considered as granted by the Author to the Editor and the Publisher from the moment of the manuscript acceptance for publication.

Other individuals and organisations can reprint the materials published in the journal only after obtaining a written consent from the Editor and the Publisher. The reprint should state the journal title, issue, and year of publication.

The Editor is not responsible for the accuracy of the information presented by the Author.


  1. If the manuscript fully complies with all requirements, it is assigned a unique registration number for further editorial use. The Author receives a confirmation letter, which states that the manuscript has been received, and contains the respective registration number.
  2. All manuscripts must undergo primary screening. The Editor reserves a right to reject the manuscript, or specify the corrections which must be made by the Author before the reviewing.
  3. All manuscripts that have passed primary screening are forwarded to one of the permanent reviewers, or to an independent expert, in accordance with the research area of the study.
  4. Reviewing is confidential for both the Author and the reviewers. The reviewer receives the manuscript which does not include authors' names or institutions.
  5. The Editor informs the Author about the reviewing results in an e-mail.
  6. If the reviewer considers the manuscript acceptable for publication without any revisions, the manuscript is forwarded to the statistical expert. After approval by the statistical expert, the manuscript is accepted for further editorial processing.
  7. If the reviewer considers the manuscript acceptable for publication after revision, the Editor forwards the manuscript and the review to the Author, suggesting that the reviewer's comments should either be incorporated in the revised manuscript, or be refuted, on the basis of valid reasoning. In this case, the submission date of the revised manuscript is considered a new submission date. The revised manuscript is reviewed again, and the reviewer confirms that all the comments have been incorporated. After approval by the reviewer, the manuscript is forwarded to the statistical expert. After approval by the statistical expert, the manuscript is accepted for further editorial processing.
  8. If the reviewer considers the manuscript unacceptable for publication, the review is forwarded to the Author. If the Author disagrees with the reviewer's opinion, they have a right to forward their well-reasoned response to the Editor. The manuscript could be either reviewed again or forwarded to the Editorial Board in order to resolve the issue. The Editorial Board, or an authorized editor, responds to the Author.
  9. All manuscripts which have been approved by the reviewer and the statistical expert are reviewed by the Editorial Board. The Editorial Board makes the decision on the manuscript publication. If the manuscript is accepted for publication, the Editor sends a letter with possible publication dates to the Author.
  10. The decision on the manuscript publication is based exclusively on the manuscript value, originality, clarity, and compliance of the study focus with the journal scope. The reports based on studies with negative results, or results which collide with the previously published materials, are processed in the same way as other reports.
  11. Original reviews are archived by the Editor for three years from the publication date.


  1. According to the requirements by the Higher Certifying Commission, the priority of the journal is the manuscripts published as part of postgraduate and doctorate dissertations. Publication date depends on a possible defence date, which the authors should specify in the cover letter.
  2. Materials for each journal issue are selected by a specific Editor-in-charge, who is appointed by the Editor-in-chief and/or the Editorial Board. The Editor-in-charge is responsible for selecting high-quality papers for publication; this selection can be based on relatively board scientific topics, or a more specialised research area.
  3. All selected papers are being processed by the scientific editor and corrector. The edited paper layout is forwarded to the author (s) for their approval.
  4. The author (s) should either confirm their approval of the publication, or forward their comments, within the requested time limits.


Subscription catalogue "Rospechat":79210 for individuals, 81196 for institutions and organisations.

Subscription catalogue "Pressa Rossii": 42432 for individuals, 42523 for institutions and organisations.


Editorial office:

101990, Moscow, Petroverigsky pereulok, 10. Cardiovascular Therapy and Prevention.

e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Publishing house:

115478, Moscow, Post Box 509, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.